Hopefully Starpharma will find a partner for its viral conjunctivitis eye drops so it can be developed and brought to market....alongside taking on Dep Gemcitabine and licensing it out to big pharma to develop
Fyi
The US Patent and Trademark Office have granted Starpharma a patent for SPL7013 ophthalmic drops for viral conjunctivitis.
The patent has been granted with broad claims for treating and preventing microbial infections of the eye and the patent term is to 2033.
SPL7013 is a proprietary dendrimer which is the active ingredient in Starpharma’s VivaGel® products. SPL7013 ophthalmic drops have already demonstrated compelling efficacy in animal models of viral conjunctivitis.
The drops have shown potent anti-viral activity, decreased infectivity and are non-irritating.
Starpharma recently completed independent market research with US Physicians / Ophthalmologists and Payers regarding the opportunity for SPL7013 ophthalmic drops. Findings from the research were extremely positive and have been of particular interest in discussions with potential partners.
Viral conjunctivitis is the most common cause of infectious conjunctivitis, affecting approximately 6 million people in the US and approximately 4 million in Europe each year.
The viral conjunctivitis market is estimated to be around US$700 million annually.
There are currently no approved therapies for viral conjunctivitis and it remains an area of significant unmet medical need globally.
So looks like we have a solution to more than a AUD $1 billion market
SPL Price at posting:
17.0¢ Sentiment: Buy Disclosure: Held
